Author

G. Deganutti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1 Biophysics· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:cryo-EM· 1 Approach:deep learning· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Organism:mouse· 1

Frequent Co-Authors

C. A. Reynolds· 5 shared G. Ladds· 3 shared K. Barkan· 3 shared B. Frenguelli· 2 shared B. Preti· 2 shared M. Leuenberger· 2 shared M. Lochner· 2 shared M. Wall· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

C. A. Reynolds

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

G. Deganutti, Y.-L. Liang, X. Zhang, M. Khoshouei, L. Clydesdale, M. J. Belousoff, H. Venugopal, T. T. Truong, A. Glukhova, A. N. Keller, K. J. Gregory, K. Leach, A. Christopoulos, R. Danev, C. A. Reynolds, , D. M. Wootten

The paper investigates how different GLP-1R agonists affect G protein activation kinetics through structural and functional analyses.

bioRxiv · Mar 10, 2021Biochemistry

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

P. Pickford, M. Lucey, R.-M. Rujan, E. R. McGlone, S. Bitsi, F. Ashford, I. R. Correa, D. Hodson, A. Tomas, G. Deganutti, C. A. Reynolds, B. M. Owen, T. M. Tan, J. Minnion, S. R. Bloom, B. Jones

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

bioRxiv · Mar 2, 2021Pharmacology & Toxicology

Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

G. Deganutti, K. Barkan, B. Preti, M. Leuenberger, M. Wall, B. Frenguelli, M. Lochner, G. Ladds, C. A. Reynolds

The paper uses molecular dynamics simulations and mutagenesis to study agonist binding to the A1 receptor, identifying new residues and binding modes of CPA-related ligands.

bioRxiv · Oct 22, 2020Pharmacology & Toxicology

A Multisite Model of Allosterism for the Adenosine A1 Receptor

G. Deganutti, K. Barkan, G. Ladds, C. A. Reynolds

The paper models allosteric behavior of the adenosine A1 receptor using simulations of PAMs and agonists to explain their functional selectivity and binding properties.

bioRxiv · Oct 14, 2020Biophysics

Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression

M. Wall, E. Hill, R. Huckstepp, K. Barkan, G. Deganutti, M. Leuenberger, B. Preti, I. Winfield, S. Carvalho, A. Suchankova, H. Wei, D. Safitri, X. Huang, W. Imlach, C. La Mache, , B. Frenguelli

The paper identifies BnOCPA as an A1R agonist that selectively activates Gαob, providing analgesia without cardiorespiratory depression.

bioRxiv · Apr 4, 2020Physiology